Evaluating heart health in adult cancer patients treated with cardiotoxic therapies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the cardiovascular health and prognosis of adult cancer patients who have been treated with potentially cardiotoxic therapies. The study will identify demographic factors associated with the onset of cardiotoxicity and determine which subgroups are more likely to experience major adverse cardiovascular events (MACE). Participants will undergo clinical, laboratory, and echocardiographic evaluations during their anticancer treatment, following current guidelines on Cardio-Oncology. The initial follow-up period for participants will be two years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients over the age of 18 at the time of evaluation
* Patients treated with potentially cardiotoxic anticancer drugs
* Patients for which complete clinical, electrocardiographic and echocardiographic data are available at first evaluation and at least at one follow-up visit.

Exclusion Criteria:

* Patients under the age of 18 at the time of evaluation
* Patients whose documentation of the first visit is not available
* Patients for whom it is not possible to obtain follow-up information through a medical visit or by telephone
* Patient with poor acoustic window for echocardiographic examination.
* Refusal of informed consent to participate in the study.

Where it's running

• Fondazione Policlinico Universitario A. Gemelli IRCCS;UOSD diagnostica cardiologica non invasiva
  Rome, Lazio, Italy Recruiting

Study contacts

• Principal investigator: Antonella Lombardo — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Antonella Lombardo
• Email: antonella.lombardo@policlinicogemelli.it
• Phone: +390630157070

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stopping heart failure medications in cancer survivors with heart dysfunction

  This study is testing if cancer survivors with improved heart function can safely stop taking their heart failure medications to see if it reduces their pill burden and side effects.

  Recruiting at 8 sites Phase 4 University Health Network, Toronto · Los Angeles, California and 13 other locations · NCT06183437

• Using statins to reduce heart problems in breast cancer patients receiving HER2 therapy

  This study is testing if adding a cholesterol-lowering medication called Lipitor can help protect the hearts of women with early-stage HER2 positive breast cancer who are getting treatment.

  Recruiting at 9 sites Phase 2 Rutgers, The State University of New Jersey · Elizabeth, New Jersey and 9 other locations · NCT05559164

• Using Sacubitril/Valsartan to prevent heart damage in breast cancer treatment

  This study is testing if the medication Sacubitril/Valsartan can help protect the hearts of women undergoing treatment for breast cancer from damage.

  Recruiting at 3 sites Phase 4 Silesian Centre for Heart Diseases · Opole, Opole Voivodeship and 3 other locations · NCT05465031

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.